GLPwatch
Papers (10401)
Page 20 of 174, ranked by citation count.
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
- Effects of dulaglutide on alcohol consumption during smoking cessation.
- Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4.
- Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions.
- Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
- Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
- Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
- Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
- Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
- Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
- Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
- Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
- Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
- Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel.
- Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).
- Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
- LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.
- Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
- GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
- Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
- Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease.
- Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
- An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
- Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
- Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
- Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation.
- Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
- Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
- Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
- Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents.
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
- The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.
- Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
- Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.
- Diabesity: therapeutic options.
- The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.
- Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
- Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
- Evolution of exenatide as a diabetes therapeutic.